Celldex Therapeutics Inc (CLDX)
36.46
-0.56
(-1.51%)
USD |
NASDAQ |
Apr 25, 10:49
Celldex Therapeutics Cash from Financing (Quarterly): 217.37M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 217.37M |
| September 30, 2023 | 0.257M |
| June 30, 2023 | 0.133M |
| March 31, 2023 | 0.694M |
| December 31, 2022 | 1.395M |
| September 30, 2022 | 2.306M |
| June 30, 2022 | 0.071M |
| March 31, 2022 | 0.304M |
| December 31, 2021 | 0.426M |
| September 30, 2021 | 271.90M |
| June 30, 2021 | -0.025M |
| March 31, 2021 | 0.074M |
| December 31, 2020 | 0.044M |
| September 30, 2020 | 4.491M |
| June 30, 2020 | 165.05M |
| March 31, 2020 | 1.637M |
| December 31, 2019 | 2.422M |
| September 30, 2019 | 2.463M |
| June 30, 2019 | 7.212M |
| March 31, 2019 | 4.16M |
| December 31, 2018 | 3.569M |
| September 30, 2018 | 5.538M |
| June 30, 2018 | 8.271M |
| March 31, 2018 | 12.06M |
| December 31, 2017 | 18.46M |
| Date | Value |
|---|---|
| September 30, 2017 | 11.27M |
| June 30, 2017 | 8.668M |
| March 31, 2017 | 12.90M |
| December 31, 2016 | 3.284M |
| September 30, 2016 | 8.298M |
| June 30, 2016 | 2.62M |
| March 31, 2016 | 0.28M |
| December 31, 2015 | 0.318M |
| September 30, 2015 | 0.736M |
| June 30, 2015 | 0.338M |
| March 31, 2015 | 191.76M |
| December 31, 2014 | 0.011M |
| September 30, 2014 | 0.304M |
| June 30, 2014 | 0.154M |
| March 31, 2014 | 0.702M |
| December 31, 2013 | 183.55M |
| September 30, 2013 | 0.622M |
| June 30, 2013 | -9.086M |
| March 31, 2013 | 114.51M |
| December 31, 2012 | 19.57M |
| September 30, 2012 | 9.58M |
| June 30, 2012 | -1.309M |
| March 31, 2012 | 51.91M |
| December 31, 2011 | 0.129M |
| September 30, 2011 | -0.023M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.025M
Minimum
Jun 2021
271.90M
Maximum
Sep 2021
35.70M
Average
1.395M
Median
Dec 2022
Cash from Financing (Quarterly) Benchmarks
| ThermoGenesis Holdings Inc | 0.217M |
| Perspective Therapeutics Inc | 0.352M |
| Electromed Inc | 0.026M |
| Xtant Medical Holdings Inc | 0.325M |
| Asensus Surgical Inc | 0.172M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -32.53M |
| Cash from Investing (Quarterly) | -171.16M |
| Free Cash Flow | -109.11M |
| Free Cash Flow Per Share (Quarterly) | -0.6376 |
| Free Cash Flow to Equity (Quarterly) | -33.20M |
| Free Cash Flow Yield | -6.18% |